Emcutix Biopharmaceuticals Ltd., in collaboration with Canada-based Mantra Pharma Inc., has announced the pan-India launch of Ureaderm, an advanced urea-based moisturizer specifically formulated for Indian skin conditions. Both companies are subsidiaries of Emcure Pharmaceuticals Ltd.
The product, available in 10% and 20% concentrations, targets the prevention and management of extremely dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis. The moisturizer is designed to restore the skin's natural moisturizing factor and significantly boost hydration levels.
Advanced Technology for Sustained Hydration
Ureaderm leverages proprietary Multilayer Fatty Acid Emulsion (MLFAE) technology to deliver enhanced and long-lasting hydration. This innovative approach enables a controlled release of urea, ensuring deep penetration and continuous moisturization for up to 72 hours.
"We understand that modern skincare demands more than regular moisturising—they require formulations grounded in rigorous science with real-world efficacy," said Sathya Narayanan, CEO of Emcutix Biopharmaceuticals Ltd. "By integrating controlled-release encapsulation with optimized urea levels, the product ensures continuous skin barrier support that provides therapeutic benefits for conditions like ichthyosis and psoriasis."
The scientific foundation for Ureaderm is substantial, with global studies demonstrating that urea concentrations between 5% and 40% are effective against dry skin conditions. The formulation goes beyond urea alone, incorporating eicosapentaenoic acid (EPA), gamma-linolenic acid (GLA), and allantoin. These components work synergistically to strengthen the skin's lipid barrier, reduce transepidermal water loss, and maintain skin softness and elasticity.
Targeted Formulations for Different Needs
The dual-strength approach addresses varying skin care requirements. The 10% formulation is positioned for adults seeking a regular skincare routine for dry skin management, while the 20% concentration provides enhanced keratolytic action specifically for those with more severe conditions like ichthyosis or psoriasis.
This differentiated approach reflects the companies' understanding of the spectrum of dry skin conditions and their varying therapeutic needs. The higher concentration provides the additional keratolytic action needed to address the excessive skin cell buildup characteristic of hyperkeratotic conditions.
Addressing Unmet Needs in Dermatological Care
Dry skin conditions affect a significant portion of the population, with hyperkeratotic disorders like psoriasis impacting approximately 2-3% of people worldwide. These conditions can significantly impact quality of life, causing discomfort, itching, and cosmetic concerns.
The launch of Ureaderm represents an important addition to the therapeutic options available for these conditions in India. By combining scientific innovation with accessibility, Emcutix aims to address a significant unmet need in dermatological care.
"Above all, we remain committed to making performance-driven, evidence-based skincare solutions both accessible and affordable for consumers," Narayanan added, highlighting the company's mission to democratize access to advanced skincare solutions.
Emcutix Biopharmaceuticals Ltd., backed by Emcure Pharmaceuticals, continues to focus on delivering innovative skincare and aesthetic solutions in the Indian market. This collaboration with Mantra Pharma demonstrates the company's commitment to bringing international expertise and technology to address local healthcare needs.
